| 摘要 |
PURPOSE: A stable crystalline form of 4-£5-methyl-3-phenylisoxazol-4-yl|benzene sulfonamide is provided. The crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations. CONSTITUTION: A pharmaceutical composition comprises a therapeutically-effective amount of crystalline Form B of 4- £5-methyl-3-phenylisoxazol-4-yl)benzene sulfonamide in association with at least one pharmaceutically acceptable carrier, adjuvant or diluent. Wherein, the form of 4-£5-methyl-3-phenylisoxazol-4yl|benzene sulfonamide has a melting point of about 170-174 OC and an IR spectrum with the peaks of 1170, 925, 844, and 729 cm-1. |
